Moderna, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Stéphane Bancel
- Full Time Employees
- 4,700
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 325 Binney Street Cambridge MA United States of America 02142
- IPO Date
- Dec 7, 2018
- CIK
- 0001682852
- Website
- modernatx.com
- Similar Companies
- Business
- Moderna, Inc. (MRNA) develops and commercializes messenger RNA (mRNA) medicines and vaccines for infectious diseases, oncology, rare diseases, and other therapeutic areas; its core products include Spikevax (mRNA-1273), the COVID-19 vaccine approved for individuals 18 years and older; mRESVIA (mRNA-1345), the respiratory syncytial virus (RSV) vaccine for adults 60 years and older approved in the U.S., Europe, Canada, and Qatar; and mNEXSPIKE (mRNA-1283), the next-generation COVID-19 vaccine approved in the U.S.; the company advances a pipeline of over 45 development programs, including seasonal influenza and combination flu/COVID vaccines, cytomegalovirus vaccine candidates, individualized neoantigen therapies (INTs) such as intismeran autogene for oncology, and rare disease treatments targeting conditions like glycogen storage disease type 1a, with 36 ongoing clinical trials encompassing nine Phase 2 and Phase 3 oncology studies. Founded in 2010 and headquartered in Cambridge, Massachusetts, with manufacturing facilities in Norwood, Massachusetts, Moderna operates globally, partnering with governments and organizations in the U.S., UK, Canada, Australia, and Europe to support research, development, and commercial supply. Recent developments include closing a five-year $1.5 billion non-dilutive term loan facility with Ares Management Credit Funds in November 2025 to enhance liquidity to $7.1-7.6 billion; launching a three-year business strategy targeting up to 10% revenue growth in 2026 through geographic expansion and new product launches, aiming to grow its seasonal vaccine franchise from three to six approved products by 2028; investing $140 million to expand its Norwood facility for onshoring drug product capabilities, completing end-to-end domestic mRNA manufacturing; and discontinuing three pipeline assets—mRNA-1010 (seasonal influenza), mRNA-1083 (influenza/COVID combo), and mRNA-3745 (glycogen storage disease type 1a)—to prioritize high-impact programs amid cost management.
Company News
Nykredit A S Acquires New Holdings in Moderna, Inc. $MRNA
Engineers Gate Manager LP Cuts Holdings in Moderna, Inc. $MRNA
Moderna CEO's Surprising Comment Gives Clues About Where Drugmaker Is Going Next
Moderna, Inc. (MRNA) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVID
Is Moderna Stock a Buy After Its Melanoma Breakthrough?
Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?
Should You Buy Moderna Stock? Why Many Wall Street Analysts Say "No."
MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going
Moderna Stock Is Soaring: What's Going On?
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
3 Bullish Setups for the Week Ahead
Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Breakfast News: Week in Review
Moderna Stock Is Surging: What's Going On?
Moderna Stock More Than Doubled in a Month. Now Comes the Hard Part
Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
Breakfast News: Why Merck Should Buy Moderna
Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?